^
Association details:
Biomarker:Chr del(9)(p21.3)
Cancer:Solid Tumor
Drug Class:PD1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

Published date:
09/23/2021
Excerpt:
Here, we performed immunogenomic analysis of data from TCGA and clinical trials of anti-PD-1/PD-L1 therapy, with a particular focus on homozygous deletion of 9p21.3 (9p21 loss), one of the most frequent genomic defects occurring in ~13% of all cancers….Notably, patients with 9p21 loss exhibited significantly lower response rates to ICT and worse outcomes, which were corroborated in eight ICT trials of >1,000 patients.
DOI:
10.1038/s41467-021-25894-9